Omnicell (OMCL)
(Delayed Data from NSDQ)
$50.14 USD
-2.32 (-4.42%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $50.16 +0.02 (0.04%) 7:58 PM ET
1-Strong Buy of 5 1
C Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$50.14 USD
-2.32 (-4.42%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $50.16 +0.02 (0.04%) 7:58 PM ET
1-Strong Buy of 5 1
C Value C Growth B Momentum B VGM
Zacks News
Omnicell (OMCL) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of 21.25% and 2.07%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Omnicell (OMCL) Faces Lingering Cost Woes, Fierce Competition
by Zacks Equity Research
Omnicell's (OMCL) second-quarter 2021 guidance includes additional freight costs, given the ongoing global market conditions.
Omnicell (OMCL) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should SPDR Portfolio S&P 600 Small Cap ETF (SPSM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPSM
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Omnicell (OMCL)-Chartwell Partner to Implement IVX Workflow
by Zacks Equity Research
Omnicell (OMCL) and Chartwell partner to implement Omnicell's IVX Workflow for the management of chemotherapy drug product preparations.
CPSI vs. OMCL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CPSI vs. OMCL: Which Stock Is the Better Value Option?
CPSI vs. OMCL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CPSI vs. OMCL: Which Stock Is the Better Value Option?
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
CPSI vs. OMCL: Which Stock Is the Better Value Option?
by Zacks Equity Research
CPSI vs. OMCL: Which Stock Is the Better Value Option?
Should SPDR Portfolio S&P 600 Small Cap ETF (SPSM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPSM
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
NXGN vs. OMCL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
NXGN vs. OMCL: Which Stock Is the Better Value Option?
LabCorp (LH) Base Line Growth Solid, COVID-Related Sales Drop
by Zacks Equity Research
LabCorp's (LH) Walgreens-partnership expands to include new integrated digital experiences.
Omnicell (OMCL) Q1 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
Omnicell's (OMCL) raises adjusted EPS guidance for 2021 , which buoys optimism.
Omnicell (OMCL) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of 23.88% and 2.65%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Hologic (HOLX) Q2 Earnings Miss Estimates, Margins Rise
by Zacks Equity Research
Hologic (HOLX) exhibited robust segmental growth in second-quarter fiscal 2021, driven by strong performance by the Diagnostics segment amid the coronavirus pandemic.
Align Technology (ALGN) Q1 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Align Technology's (ALGN) segments report solid Q1 sales across geographies despite the pandemic-led business challenges.
Accuray (ARAY) Posts Breakeven Q3 Earnings, Beats on Revenues
by Zacks Equity Research
Accuray (ARAY) registers growth in Service and Product revenues during fiscal Q3.
Illumina (ILMN) Q1 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Illumina (ILMN) exhibits an impressive performance by its Instruments segment in the first quarter of 2021 despite pandemic-led business disruptions.
Stryker (SYK) Earnings and Revenues Miss Estimates in Q1
by Zacks Equity Research
Stryker's (SYK) first-quarter earnings reflect strong performance across Orthopaedics and Neurotechnology and Spine segments.
Masimo (MASI) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Masimo (MASI) continues to gain from its key Product segment, which makes a solid progress in Q1.
Ecolab (ECL) Q1 Earnings Miss, Revenues Surpass Estimates
by Zacks Equity Research
Although Ecolab's (ECL) first-quarter results reflect weakness in the Global Industrial and Institutional segments, its Global Healthcare and Life Sciences unit shows strength.
Omnicell (OMCL) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Edwards Lifesciences (EW) Beats on Q1 Earnings, Margins Down
by Zacks Equity Research
Despite coronavirus-led business challenges, Edwards Lifesciences (EW) witnessed robust segmental performances in Q1.